These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38967523)

  • 1. METTL1/FOXM1 promotes lung adenocarcinoma progression and gefitinib resistance by inhibiting PTPN13 expression.
    Peng W; Fu J; Zhou L; Duan H
    Cancer Med; 2024 Jul; 13(13):e7420. PubMed ID: 38967523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FTO/m6A mediates miR-138-5p maturation and regulates gefitinib resistance of lung adenocarcinoma cells by miR-138-5p/LCN2 axis.
    Ding D; Shang W; Shi K; Ying J; Wang L; Chen Z; Zhang C
    BMC Cancer; 2024 Oct; 24(1):1270. PubMed ID: 39394098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIF-1α-HPRT1 axis promotes tumorigenesis and gefitinib resistance by enhancing purine metabolism in EGFR-mutant lung adenocarcinoma.
    Geng P; Ye F; Dou P; Hu C; He J; Zhao J; Li Q; Bao M; Li X; Liu X; Xu G
    J Exp Clin Cancer Res; 2024 Sep; 43(1):269. PubMed ID: 39343971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-risk histological subtype-related FAM83A hijacked FOXM1 transcriptional regulation to promote malignant progression in lung adenocarcinoma.
    Fei W; Yan Y; Liu G; Peng B; Liu Y; Chen Q
    PeerJ; 2023; 11():e16306. PubMed ID: 37904848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
    Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
    Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells.
    Xu N; Zhang X; Wang X; Ge HY; Wang XY; Garfield D; Yang P; Song YL; Bai CX
    Acta Pharmacol Sin; 2012 May; 33(5):675-81. PubMed ID: 22447226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m
    Lin X; Ye R; Li Z; Zhang B; Huang Y; Du J; Wang B; Meng H; Xian H; Yang X; Zhang X; Zhong Y; Huang Z
    Drug Resist Updat; 2023 Jan; 66():100908. PubMed ID: 36493511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circ-MMP2 (circ-0039411) induced by FOXM1 promotes the proliferation and migration of lung adenocarcinoma cells in vitro and in vivo.
    Lv X; Huang H; Feng H; Wei Z
    Cell Death Dis; 2020 Jun; 11(6):426. PubMed ID: 32513952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop.
    Wang Y; Zhang W; Wen L; Yang H; Wen M; Yun Y; Zhao L; Zhu X; Tian L; Luo E; Li Y; Liu W; Wen N
    Oncotarget; 2016 Sep; 7(37):59245-59259. PubMed ID: 27494877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma.
    He J; Lan X; Liu X; Deng C; Luo H; Wang Y; Kang P; Sun Z; Zhao L; Zhou X
    BMC Cancer; 2023 Mar; 23(1):266. PubMed ID: 36959566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propofol disrupts cell carcinogenesis and aerobic glycolysis by regulating circTADA2A/miR-455-3p/FOXM1 axis in lung cancer.
    Zhao H; Wei H; He J; Wang D; Li W; Wang Y; Ai Y; Yang J
    Cell Cycle; 2020 Oct; 19(19):2538-2552. PubMed ID: 32857667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
    Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
    J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma.
    Song H; Liu D; Wang L; Liu K; Chen C; Wang L; Ren Y; Ju B; Zhong F; Jiang X; Wang G; Chen ZS; Zou C
    Mol Cancer; 2022 Feb; 21(1):43. PubMed ID: 35144642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depleting hsa_circ_0000567 suppresses acquired gefitinib resistance and proliferation of lung adenocarcinoma cells through regulating the miR-377-3p / ZFX axis: an in vitro and in vivo study.
    Wang L; Li M; Lian R
    Histol Histopathol; 2022 Jul; 37(7):637-654. PubMed ID: 35133000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression.
    Zhang H; Wang SQ; Wang L; Lin H; Zhu JB; Chen R; Li LF; Cheng YD; Duan CJ; Zhang CF
    Cell Death Dis; 2022 Jul; 13(7):657. PubMed ID: 35902569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyphyllin I ameliorates gefitinib resistance and inhibits the VEGF/VEGFR2/p38 pathway by targeting HIF-1a in lung adenocarcinoma.
    Zhang D; Tian X; Wang Y; Liu F; Zhang J; Wang H; Zhang N; Yan T; Lin C; Shi Z; Liu R; Jiang S
    Phytomedicine; 2024 Jul; 129():155690. PubMed ID: 38761523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USF1-induced overexpression of long noncoding RNA WDFY3-AS2 promotes lung adenocarcinoma progression via targeting miR-491-5p/ZNF703 axis.
    Ren P; Hong X; Chang L; Xing L; Zhang H
    Mol Carcinog; 2020 Aug; 59(8):875-885. PubMed ID: 32275336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of EMG1 in lung adenocarcinoma progression: Implications for prognosis and immune cell infiltration.
    Wu X; Wu Z; Xie Z; Huang H; Wang Y; Lv K; Yang H; Liu X
    Int Immunopharmacol; 2024 Sep; 138():112553. PubMed ID: 38943975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-145-5p Modulates Gefitinib Resistance by Targeting NRAS and MEST in Non-Small Cell Lung Cancer.
    Yu C; Li B; Wang J; Zhang Z; Li S; Lei S; Wang Q
    Ann Clin Lab Sci; 2021 Sep; 51(5):625-637. PubMed ID: 34686504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.